STUDY OF THE HYPOGLYCEMIC AND CARDIOPROTECTIVE EFFECT OF EMPAGLIFLOZIN IN THERAPY OF PATIENTS WITH TYPE 2 DIABETES MELLITUS. World Bulletin of Public Health, v. 18, p. 9–14, 11 Jan.2023.